Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:CORT News 16 December 2025 - 2 January 2026

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept shares closed down 50.4% at $34.80 after the FDA declined to approve relacorilant for Cushing’s-related hypertension, citing insufficient evidence. Truist cut its price target to $50 and Wolfe downgraded the stock to Underperform with a $30 target. The FDA set a July 11, 2026 decision date for relacorilant in ovarian cancer. U.S. markets are closed Thursday for New Year’s Day.
1 January 2026
··
Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

Corcept Therapeutics shares fell 50.4% to $34.80 after the FDA declined to approve relacorilant for Cushing’s-related hypertension, citing a need for more evidence of effectiveness. The company plans to meet with the agency to discuss next steps. Wolfe Research downgraded the stock and removed projected sales for the indication. Trading volume reached about 20.16 million shares.
1 January 2026
··
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept shares plunged about 50% in after-hours trading after the FDA declined to approve relacorilant for hypertension linked to hypercortisolism. The agency requested more evidence of effectiveness, despite acknowledging trial data. Wolfe Research downgraded the stock and slashed its price target. Corcept said it plans to meet with the FDA to discuss next steps.
1 January 2026
··
Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

Corcept shares plunged nearly 50% to $35.31 after the FDA rejected relacorilant for Cushing’s-related hypertension, citing insufficient evidence of effectiveness. The move erased about $3.7 billion in market value. Corcept said it will meet with the FDA to discuss next steps. The company is also awaiting a July 2026 FDA decision on relacorilant in ovarian cancer.
31 December 2025
··
Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept Therapeutics shares fell 8.9% to $72.72 in early afternoon trading Tuesday as investors awaited the FDA’s decision on relacorilant, due later in the day. SEC filings showed CEO Joseph Belanoff and Chief Business Officer Gary Charles Robb exercised stock options and withheld shares for taxes. About 897,000 shares changed hands. The drop outpaced declines in major biotech indexes.
30 December 2025
··
Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics Incorporated (NASDAQ: CORT) ended Tuesday, December 16, 2025, sharply lower after a strong 2025 run that had pushed expectations—and valuation—into the spotlight. Shares closed at $79.44, down $7.86 (about 9%) from the prior close, after trading as low as $78.84 on the day. The day’s narrative around Corcept Therapeutics stock wasn’t driven by a single blockbuster headline like an FDA decision or a clinical-trial halt. Instead, it was a classic “high-expectations” session: fresh sell-side coverage, valuation-focused commentary, and investors recalibrating risk ahead of a major FDA catalyst for relacorilant later this month. Below is a complete roundup of
16 December 2025
···

Stock Market Today

RBC stock heads into new week near C$233 after Canada jobs surprise

RBC stock heads into new week near C$233 after Canada jobs surprise

7 February 2026
Royal Bank of Canada shares closed Friday up 0.7% at C$232.72, trailing gains by other major Canadian banks. Canada’s main stock index surged 1.5% as metals rebounded. January jobs data showed a loss of 24,800 positions but a lower 6.5% unemployment rate. RBC’s Q1 earnings are due Feb. 26.
IHC stock price holds near 400 dirhams after Abu Dhabi group flags phishing emails

IHC stock price holds near 400 dirhams after Abu Dhabi group flags phishing emails

7 February 2026
International Holding Company PJSC warned investors of phishing scams using its name and logo, according to an ADX disclosure. IHC shares closed flat at 399.60 dirhams on Friday, trading in a narrow range with 237,109 shares changing hands. UAE equities ended the week slightly higher as traders watched Iran-U.S. talks and oil prices.
Go toTop